第四期非小细胞肺癌免疫治疗时间的预后影响
Jorge Raul Vazquez-Urrutia1, Max Greenberg1, Junjia Zhu2
1Department of Medicine, Penn State Health Milton S. Hershey Medical Center, Hershey, PA 17033, USA.
World journal of oncology
|September 27, 2024
概括
在化疗后30天内开始免疫治疗显著改善了第四阶段非小细胞肺癌 (NSCLC) 患者的生存率. 延迟免疫治疗与更糟糕的整体生存结果有关.
科学领域:
- 在瘤学瘤学.
- 临床医学 临床医学
- 癌症研究 癌症研究
背景情况:
- 第四期非小细胞肺癌 (NSCLC) 治疗通常结合化疗和免疫疗法.
- 针对免疫疗法启动的分子分析可能会在化疗开始后造成延迟.
- 延迟免疫治疗对患者结果的影响需要研究.
研究的目的:
- 评估推迟IV期NSCLC患者免疫疗法启动的重要性.
- 评估免疫治疗时间对整体存活时间 (OS) 的影响.
主要方法:
- 一项使用国家癌症数据库 (NCBD) 从2017-2018年进行的回顾性队列研究.
- 患有IV期NSCLC的患者在30天内接受了第一线多剂化疗.
- 分析包括30天内接受免疫疗法,31-60天内接受免疫疗法或仅接受化疗的组;使用了Kaplan-Meier和Cox回归分析.
主要成果:
- 分析了99008名患者的队列.
- 早期免疫疗法 (在30天内) 与延迟免疫疗法 (HR=0.74,P=0.0003) 相比显示显著更大的OS.
- 与更糟糕的OS相关的因素包括延迟免疫疗法,年龄较大,男性性别,白人种族,非腺癌组织学,更高的N阶段,辐射使用和肝转移.
结论:
- 在化疗后30天内开始免疫治疗显著改善了第四阶段NSCLC的存活率.
- 推迟免疫治疗与较差的整体存活率有关.
- 及时给予免疫治疗对于优化第四阶段NSCLC的结果至关重要.
更多相关视频
10:29Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
Published on: August 14, 2019
10.5K
09:32Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
Published on: February 8, 2018
14.5K
相关概念视频
01:27Tumor Immunotherapy
491
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
491
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
01:30Cancer Vaccines
345
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
345
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K